Cytomos Ltd.

Cytomos is the trailblazing, investor-backed innovator behind AuraCyt™ technology. Cytomos is a purpose and impact driven organisation that is successfully repurposing microelectronics to enable the cost-effective use of biotechnologies and allow economies of scale. Our mission is to become the undisputed PAT partner for real-time-single-cell analytics. AuraCyt™ from Cytomos is harnessing the combined power of dielectric spectroscopy and consumer microelectronics to generate multidimensional data for single cells, without the need for labels. AuraCyt™ was developed by an in-house team, and we are continuing to work on a number of proof-of-concept studies in partnership with exciting large biotechs and pharma companies who see the value in this novel technology. With huge potential for applications across a range of markets, we are continuing to engage with well-known force multipliers in the bioprocessing and cell and gene therapy space, including bioprocessing solution market leaders and cutting-edge TechBio partners set to dominate the Advanced Therapy and Medical Products (ATMP) space, who see the ease of use and positive impact that AuraCyt™ is having on their work. AuraCyt™ will accelerate biological drug discovery and development, and it will streamline manufacturing, with real-time monitoring and better prospects for automation.